CompletedPhase 2

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

United States149 participantsStarted 2015-03-27

Plain-language summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. At least 3 swollen joints and at least 3 tender joints at Screening and at baseline
✓. C-reactive protein (CRP) greater than or equal to (\>=) 0.3 milligram (mg)/deciliter (dL) at Screening from the central laboratory

Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 24

Timeframe: Week 24

NCT IDNCT02319759

SponsorJanssen Research & Development, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-05-31

Results submitted2020-08-12